我們僅此通知您有關我們的2025年中期報告已上載於本公司網站(www.ccland.com.hk)及「披露易」網站(www.hkexnews.hk)。 要在我們的網站上取得2025年中期報告，點擊「選單」並從「企業披露」下的「財務報告╱環境、社會及管治資料」選擇檢視2025年中 期報告。如您希望收取2025年中期報告的印刷本，請於本公司網站「企業披露」下的「以電子方式發布公司通訊」選擇「回覆表格」，填 妥回覆表格A部分並交回我們的股份過戶登記處香港分處卓佳證券登記有限公司，地址為香港夏慤道16號遠東金融中心17樓。 C C Land Holdings Limited （於百慕達註冊成立的有限公司） 中渝置地控股有限公司 （股份代號：1224） 致股東的通知信函 致股東： 發布公司通訊1 我們須要取得我們的登記股東的電子聯絡資料。該等資料將用於我們向有關登記股東以電郵發送我們的公司通訊已於我們的網 站發布的通知信函及可供採取行動的公司通訊2 的電子版本。如任何登記股東未有提供他們的電子聯絡資料或所提供的電子聯絡 資料已更改，請填妥上述可於本公司網站下載的回覆表格B部分並盡快交回我們的股份過戶登記處香港分處卓佳證 ...

目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 管理層討論及分析 | 3 | | 權益披露 | 9 | | 其他資料 | 11 | | 綜合損益表 | 13 | | 綜合全面收益表 | 14 | | 綜合財務狀況表 | 15 | | 綜合權益變動表 | 16 | | 簡明綜合現金流量表 | 17 | | 簡明綜合財務資料附註 | 18 | 中渝置地控股有限公司 2025年中期報告 1 公司資料 董事 執行董事 張松橋先生 （主席） 林孝文醫生 （副主席兼董事總經理） 黃志強先生 （副主席） 梁偉輝先生 張渝翎女士 獨立非執行董事 林健鋒先生 梁宇銘先生 陸宇經先生 審核委員會 林健鋒先生 （主席） 梁宇銘先生 陸宇經先生 提名委員會 張松橋先生 （主席） 張渝翎女士 林健鋒先生 梁宇銘先生 陸宇經先生 薪酬委員會 梁宇銘先生 （主席） 張松橋先生 林孝文醫生 林健鋒先生 陸宇經先生 授權代表 林孝文醫生 梁偉輝先生 公司秘書 張鳳儀女士 網址 www.ccland.com.hk 證券代號 股份 1224.HK 2025年到期300百萬美元的5.20%有擔保票據 40850.H ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: C C Land Holdings Limited 中渝置地控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01224 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.1 | HKD | | 2,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0. ...

中渝置地(01224)发布截至2025年6月30日止6个月的中期业绩，收入2.5亿港元，同比增加2.56%;股东应 占亏损3675.4万港元，上年同期股东应占溢利9100.6万港元，同比盈转亏;每股基本亏损0.95港仙。 ...

智通财经APP讯，中渝置地(01224)发布截至2025年6月30日止6个月的中期业绩，收入2.5亿港元，同比 增加2.56%;股东应占亏损3675.4万港元，上年同期股东应占溢利9100.6万港元，同比盈转亏;每股基本亏 损0.95港仙。 ...

格隆汇8月21日丨中渝置地(01224.HK)发布公告，截至2025年6月30日止六个月，实现收入2.50亿港元， 同比增加2.6%；毛利为2.43亿港元，同比增加6.4%；母公司普通权益拥有人应占本期间亏损3675.4万港 元，上年同期母公司普通权益拥有人应占盈利9100.6万港元；基本每股亏损0.95港仙。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 C C Land Holdings Limited 中 渝 置 地 控 股 有 限 公 司 ( 於百慕達註冊成立的有限公司 ) 網址： www.ccland.com.hk （股份代號︰1224） 截至 2025 年 6 月 30 日止 6 個月的中期業績 中渝置地控股有限公司（「本公司」）董事會（「董事會」）公佈本公司及其附屬公司（合稱「本集團」） 截至2025年6月30日止6個月的未經審核綜合業績，連同2024年同期的比較數字如下： 綜合損益表 | | | 截至 | 6 月 30 | 日止 6 | 個月 | | --- | --- | --- | --- | --- | --- | | | | 2025 年 | | | 2024 年 | | | | 千港元 | | | 千港元 | | | 附註 | (未經審核) | | | (未經審核) | | 收入 | 4 | 250,337 | | | 244,0 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 中 渝 置 地 控 股 有 限 公 司 （於百慕達註冊成立的有限公司） 網址︰ www.ccland.com.hk （股份代號︰1224） 董 事 會 召 開 日 期 中渝置地控股有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於 2025年8月21日（星期四）舉行董事會會議，藉以（其中包括）批准刊發本公司及其 附屬公司截至2025年6月30日止六個月的中期業績公告，以及考慮派發中期股息。 承董事會命 副主席兼董事總經理 林孝文 香港，2025 年 8 月 8 日 於本公告日期，董事會包括執行董事張松橋先生、林孝文醫生、黃志強先生 、 梁偉輝先生 及張渝翎女士；以及獨立非執行董事林健鋒先生、梁宇銘先生及陸宇經先生。 C C Land Holdings Limited ...

Group 1 - The market capitalization of the Hong Kong securities market increased to HKD 44.9 trillion as of July 2025, representing a year-on-year growth of 44% from HKD 31.1 trillion [1] - The growth is attributed to favorable policies, the return of Chinese concept stocks, and reforms within the Hong Kong stock market, which enhances its financing capabilities and attracts more enterprises and capital [1] Group 2 - Baifu Holdings announced the sale of a 1.71% stake in Guangzhou Yujian Xiaomian for HKD 48 million, reducing its ownership from approximately 17.16% to 15.46% [2] - The company reported a 24.4% decline in revenue and a 59.5% increase in net loss for 2024, indicating financial struggles that may have prompted the sale [2] - Yujian Xiaomian has submitted a prospectus for an IPO on the Hong Kong main board, with CMB International as the sole sponsor [2] Group 3 - Zhongyu Land expects a shareholder loss of approximately HKD 40 million for the first half of the year, a significant decline from a profit of HKD 91 million in the same period last year [3] - The loss is primarily due to reduced contributions from joint ventures and decreased fair value gains from investment properties in the UK, partially offset by exchange gains from the appreciation of GBP against HKD [3] Group 4 - ZTE Corporation completed the issuance of HKD 3.584 billion in zero-coupon convertible bonds, maturing in 2030, with net proceeds of approximately RMB 35.43 billion after expenses [4] - The funds will be used to enhance research and development in computing power products, which is expected to strengthen ZTE's competitiveness in AI and 5G sectors [4] - The bonds have been listed on the Hong Kong Stock Exchange, with trading permissions effective from August 6 [4] Group 5 - The Hang Seng Index closed at 24,910.63, with a slight increase of 0.03% on August 6 [5] - The Hang Seng Tech Index rose by 0.20% to 5,532.17, while the National Enterprises Index decreased by 0.21% to 8,932.68 [5]

Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]